Andrew Krueger

Estimated cost of treating myasthenia gravis in an insured U.S. population.

Introduction: In this study we estimated the costs paid by U.S. health plans for treating myasthenia gravis (MG) in 2009 and determined the major cost drivers. Methods: One hundred thirteen MG patients were matched by propensity scores with 339 non‐MG patients from a comprehensive health‐care insurance database. The mean annual costs paid by the health plan for treating MG, costs by place of service, and costs for intravenous immunoglobulin (IVIg) and plasma exchange were determined. Results: Mean annual costs paid by the health plan per MG patient were

Health Insurance Paid Costs and Drivers of Costs for Patients With Crohn’s Disease in the United States

20,190 (SEM

Diagnoses, procedures, drug utilization, comorbidities, and cost of health care for people with epilepsy in 2012

4,763) and costs attributable to treating MG were

Cost analysis of myasthenia gravis from a large U.S. insurance database

15,675. Home health services accounted for 23% of MG patient costs and represented almost exclusively IVIg infusion costs. Six MG patients had a total of 136 outpatient IVIg infusions at an average annual cost of

Common comorbidities in women and men with epilepsy and the relationship between number of comorbidities and health plan paid costs in 2010

109,463 ±

Health plan paid cost of epilepsy in 2009 in the U.S.

57,303. Conclusions: The estimated annual health plan paid costs for treating MG were

Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy

15,675. Home health services represented 23% of MG patient costs, largely driven by IVIg administration. Muscle Nerve, 2012

Analgesic opioid use in a health-insured epilepsy population during 2012: Response to Derakhshan

OBJECTIVES:The cost of medical care for Crohn’s disease (CD) and comorbidities in the era of biologics is unclear. We examined insurance claims data from US health plans to understand this relationship.METHODS:Longitudinal CD patient data and reimbursement information from 11 health plans engaged with Accordant Health Services between 2011 and 2013 were analyzed. The analysis considered data for all CD patients and for the patient subgroup ≤20 years and >20 years of age. Descriptive statistics measured the mean health-plan paid costs per patient, the relative cost contribution of anti-tumor necrosis factor (TNF) agents, and health care costs for 31 specific comorbid conditions among CD patients.RESULTS:Overall, there were 5,090 CD patients (57% women) of which 587 CD patients were ≤20 years of age. The mean health-plan paid cost per member per year was

Analgesic opioid use in a health-insured epilepsy population during 2012

18,637 (s.d.

Mo1317 Health Plan Paid Costs and Drivers of Health Care Costs for Patients With Crohn's Disease Insured At Six Different Commercial Health Plans in the United States

32,023) for all CD patients,